Some disheartening candor on MS drug pricing

It’s not just R&D driving up multiple sclerosis drug costs. It’s competition between drug makers, as well as corporate growth objectives, that have dictated what patients ultimately pay for their MS medications, according to a new report in the journal Neurology. 

The study cites four drug company executives who speak about pricing. One put it quite bluntly: “I would say the rationales for the price increases are purely what can maximize profit. There’s no other rationale for it, because costs have not gone up by 10% or 15%; you know, the costs have probably gone down.” 

Read more.